Literature DB >> 10757438

Risk factors, pregnancy complications, and prevention of hypertensive disorders in women with pregravid diabetes mellitus.

B M Sibai1.   

Abstract

OBJECTIVE: To review the rate, risk factors, and potential prevention of preeclampsia in women with pregravid diabetes mellitus.
METHODS: Detailed review of recent English literature describing pregnancy outcome in women with pregravid insulin-dependent diabetes mellitus (Type 1 diabetes). The primary focus of the review is risk factors for preeclampsia and potential methods suggested for prevention of preeclampsia. In addition, pitfalls in diagnosis of preeclampsia will be emphasized.
RESULTS: The reported rate of preeclampsia ranged from 9% to 66%. This rate increased with increased severity of diabetes by White's classification, with the highest rate reported in women with pregravid diabetic nephropathy. Risk factors identified for preeclampsia were nulliparity, chronic hypertension, microalbuminuria prior to pregnancy, nephropathy, and poor glycemic control early in pregnancy. There is lack of agreement among reports in the literature concerning criteria used to diagnose preeclampsia. There are two randomized trials that included women with Type 1 diabetes who were randomized to receive either low-dose aspirin or placebo. There was no reduction in the rate of preeclampsia with low-dose aspirin in either trial.
CONCLUSIONS: In women with pregravid Type 1 diabetes, the rates of preeclampsia and adverse neonatal outcome increase with increased severity of diabetes. Low-dose aspirin does not reduce rate of preeclampsia in such women. Further studies should address the role of good glycemic control prior to 20 weeks gestation and prevention of microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10757438     DOI: 10.1002/(SICI)1520-6661(200001/02)9:1<62::AID-MFM13>3.0.CO;2-6

Source DB:  PubMed          Journal:  J Matern Fetal Med        ISSN: 1057-0802


  7 in total

Review 1.  Hypertension and the pregnancy complicated by diabetes.

Authors:  Gustavo F Leguizamón; Natalia P Zeff; Alberto Fernández
Journal:  Curr Diab Rep       Date:  2006-08       Impact factor: 4.810

Review 2.  Pregnancy in women with diabetic nephropathy.

Authors:  Donatella Spotti
Journal:  J Nephrol       Date:  2018-11-15       Impact factor: 3.902

Review 3.  Pregnancy-Related Hypertensive Disorders and Immigrant Status: A Systematic Review and Meta-analysis of Epidemiological Studies.

Authors:  Mulubrhan F Mogos; Abraham A Salinas-Miranda; Jason L Salemi; Imelda M Medina; Hamisu M Salihu
Journal:  J Immigr Minor Health       Date:  2017-12

4.  A multicentre matched case control study of risk factors for preeclampsia in healthy women in Pakistan.

Authors:  Uzma Shamsi; Juanita Hatcher; Azra Shamsi; Nadeem Zuberi; Zeeshan Qadri; Sarah Saleem
Journal:  BMC Womens Health       Date:  2010-04-30       Impact factor: 2.809

5.  The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes.

Authors:  Allison L Cohen; Julia B Wenger; Tamarra James-Todd; Brooke M Lamparello; Elizabeth Halprin; Shanti Serdy; Shuling Fan; Gary L Horowitz; Kee-Hak Lim; Sarosh Rana; Tamara C Takoudes; Jennifer A Wyckoff; Ravi Thadhani; S Ananth Karumanchi; Florence M Brown
Journal:  Hypertens Pregnancy       Date:  2013-12-19       Impact factor: 2.108

6.  Adequately diversified dietary intake and iron and folic acid supplementation during pregnancy is associated with reduced occurrence of symptoms suggestive of pre-eclampsia or eclampsia in Indian women.

Authors:  Sutapa Agrawal; Jasmine Fledderjohann; Sukumar Vellakkal; David Stuckler
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

7.  Glycemic control and fetal growth of women with diabetes mellitus and subsequent hypertensive disorders of pregnancy.

Authors:  Mamoru Morikawa; Emi Kato-Hirayama; Michinori Mayama; Yoshihiro Saito; Kinuko Nakagawa; Takeshi Umazume; Kentaro Chiba; Satoshi Kawaguchi; Kazuhiko Okuyama; Hidemichi Watari
Journal:  PLoS One       Date:  2020-03-16       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.